This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Select Medical Rises 50.2% YTD: Take Profits or Bet on More Gains?
by Zacks Equity Research
SEM's profitability is being impacted by rising costs and expenses.
Teladoc Stock Rises 12% as Jefferies Boosts Price Target on BetterHelp
by Zacks Equity Research
TDOC's stock benefits from improving web traffic in its BetterHelp platform.
Community Health's Arm Northwest Urgent Buys 10 Arizona Facilities
by Zacks Equity Research
CYH expects the acquisition from Carbon Health to be completed in the fourth quarter of 2024.
Pediatrix Medical Up 45.8% in 3 Months: Is it Too Late to Jump In?
by Zacks Equity Research
MD remains one of the best-positioned pediatric service providers with favorable valuation to achieve margin improvement.
Beat the Market Like Zacks: CareDx, Fair Isaac, 3M in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 292.31% and 37.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix (BDSX) delivered earnings and revenue surprises of 6.67% and 5.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
How CareDx (CDNA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 24.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -57.14% and 3.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?